Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis

Akoury, Elie; Luna, Ana Sofia Ramirez Garcia; Ahangar, Pouyan; Gao, Xiaoya; Zolotarov, Pylyp; Weber, Michael H.; Rosenzweig, Derek H.

doi:10.3390/jcm8081212

Cited by 10 publications

(7 citation statements)

References 66 publications

(89 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Distant metastasis is the leading cause of mortality in people with lung cancer and is present in a high percentage of patients at the time of diagnosis ( 17 ). The skeletal system is a predilection site for distant lung cancer metastasis ( 18 ). A study has shown that the incidence of LCBM is about 10–15%, while the incidence of bone metastasis in advanced lung cancer is as high as 30–40% ( 19 ).…”

Section: Discussionmentioning

confidence: 99%

Identification of the potential ferroptosis key genes in lung cancer with bone metastasis

Zhou,

Xu,

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

Background To identify the potential key genes of ferroptosis in the pathogenesis of lung cancer with bone metastasis (LCBM) by bioinformatics analysis to provide new targets for treating LCBM and an indicator for early monitoring. Methods We first obtained differentially expressed genes (DEGs) associated with ferroptosis from the Gene Expression Omnibus (GEO) database. MiRWalk 2.0 was used to predict the key microRNAs (miRNAs) and construct related gene-miRNA interaction networks. The functional enrichment analysis of key miRNAs was performed using the miEAA database. Finally, the clinical data of 105 lung cancer patients were retrospectively analyzed, and logistic regression analysis was conducted to assess the relationship between serum alkaline phosphatase (ALP), neuron-specific enolase (NSE), and bone metastasis in lung cancer patients, and a receiver operating characteristic (ROC) curve was drawn. Results We identified 15 ferroptosis-related genes that were differentially expressed in lung cancer bone metastasis. GO and KEGG enrichment analyses suggested that these genes may affect the oxidative stress response, hypoxia response, rough endoplasmic reticulum, mitochondrial outer membrane, iron-sulfur cluster binding, virus receptor activity, central carbon metabolism in cancer, the interleukin-17 (IL-17) signaling pathway, and other aspects to participate in the occurrence and development of lung cancer bone metastasis. Among the 105 lung cancer patients included in the study, 39 cases had bone metastasis, and the incidence rate was 37.14%. A high Eastern Cooperative Oncology Group (ECOG) score and serum ALP and NSE overexpression were associated with bone metastasis in patients with lung cancer. By assessing the risk of bone metastasis in patients with lung cancer, we found that the Area Under Curves (AUCs) of serum ALP and NSE alone and combined were >0.70. Conclusions The differentially expressed ferroptosis-related genes and predicted miRNA regulatory network in lung cancer bone metastasis and the related functional enrichment analysis provide new targets for the treatment of lung cancer bone metastasis. At the same time, from a serological perspective, it was found that early monitoring of serum ALP and NSE expression in patients with lung cancer could be considered to assess the risk of bone metastasis in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of the potential ferroptosis key genes in lung cancer with bone metastasis

Zhou,

Xu,

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

show abstract

“…In the United States in 2018, it was reported that lung cancer is accountable for 234,030 new cases and 154,050 deaths. Tobacco smoking is one of the most widely recognized risk factor contributing to lung cancer [109]. Lung cancer can be classified into two types, (1) non-small cell lung cancer (NSCLC), which tends to respond poorly to chemotherapy and radiation therapy; and (2) small cell lung cancer (SCLC)-this group is not common and is categorized by high proliferation rate and also sensitivity to combined chemotherapy and radiation therapy in limited-stage carcinoma cases [109].…”

Section: Lung Cancermentioning

confidence: 99%

Bisphosphonate-Based Conjugates and Derivatives as Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer

Mbese

Aderibigbe

2021

IJMS

View full text Add to dashboard Cite

Metastatic bone cancer occurs in every type of cancer but is prevalent in lung, breast, and prostate cancers. These metastases can cause extensive morbidity, including a range of skeletal-related events, often painful and linked with substantial hospital resource usage. The treatment used is a combination of chemotherapy and surgery. However, anticancer drugs are still limited due to severe side effects, drug resistance, poor blood supply, and non-specific drug uptake, necessitating high toxic doses. Bisphosphonates are the main class of drugs utilized to inhibit metastatic bone cancer. It is also used for the treatment of osteoporosis and other bone diseases. However, bisphosphonate also suffers from serious side effects. Thus, there is a serious need to develop bisphosphonate conjugates with promising therapeutic outcomes for treating metastatic bone cancer and osteoporosis. This review article focuses on the biological outcomes of designed bisphosphonate-based conjugates for the treatment of metastatic bone cancer and osteoporosis.

show abstract

“…We have created a dedicated section for bone metastasis and tumour dormancy. Across these organs, metastasis to the skeletal system is found to occur commonly (181)(182)(183)(184)(185). After initial tumour growth in the organ of origin, tumours cells undergo changes in cell signalling and cell-cell interactions such as reduced intercellular adhesion (186,187).…”

Section: Tissue-specific Vascular Niches and Vascular Changesmentioning

confidence: 99%

Diversity of Vascular Niches in Bones and Joints During Homeostasis, Ageing, and Diseases

et al. 2021

View full text Add to dashboard Cite

The bones and joints in the skeletal system are composed of diverse cell types, including vascular niches, bone cells, connective tissue cells and mineral deposits and regulate whole-body homeostasis. The capacity of maintaining strength and generation of blood lineages lies within the skeletal system. Bone harbours blood and immune cells and their progenitors, and vascular cells provide several immune cell type niches. Blood vessels in bone are phenotypically and functionally diverse, with distinct capillary subtypes exhibiting striking changes with age. The bone vasculature has a special impact on osteogenesis and haematopoiesis, and dysregulation of the vasculature is associated with diverse blood and bone diseases. Ageing is associated with perturbed haematopoiesis, loss of osteogenesis, increased adipogenesis and diminished immune response and immune cell production. Endothelial and perivascular cells impact immune cell production and play a crucial role during inflammation. Here, we discuss normal and maladapted vascular niches in bone during development, homeostasis, ageing and bone diseases such as rheumatoid arthritis and osteoarthritis. Further, we discuss the role of vascular niches during bone malignancy.

show abstract

Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis

Cited by 10 publications

References 66 publications

Identification of the potential ferroptosis key genes in lung cancer with bone metastasis

Identification of the potential ferroptosis key genes in lung cancer with bone metastasis

Bisphosphonate-Based Conjugates and Derivatives as Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer

Diversity of Vascular Niches in Bones and Joints During Homeostasis, Ageing, and Diseases

Contact Info

Product

Resources

About